High-throughput Proteomics Identifies THEMIS2 as Independent Biomarker of Treatment-free Survival in Untreated CLLPaul J. Hengeveld, Anton W. Langerak, Julie Dubois et al.|HemaSphere|2023Cited by 5
High-Throughput Proteomics Identifies THEMIS2 As Biomarker of Inferior Treatment-Free Survival in Chronic Lymphocytic LeukemiaPaul J. Hengeveld, Mark‐David Levin, P. Martijn Kolijn et al.|Blood|2022Cited by 0